Advertisement

Topics

PhaseBio Pharmaceuticals, Inc. Company Profile

23:22 EDT 29th April 2016 | BioPortfolio

PhaseBio Pharmaceuticals, Inc. (PhaseBio), located in Research Triangle Park, NC, is a development stage, privately held protein engineering company focused on developing the next generation of biopharmaceuticals. The company's versatile technology is based on biopolymers of elastin-like repeating subunits to which drugs can be attached or peptides and proteins genetically fused, enhancing the pharmacology and delivery of therapeutics.


News Articles [641 Associated News Articles listed on BioPortfolio]

FDA grants orphan status to cardiomyopathy treatment from PhaseBio

PhaseBio Pharmaceuticals' injectable Vasomera has been awarded orphan drug status by the FDA as a treatment for dystrophinopa -More- 

PhaseBio begins PE0139 Phase IIa trial to treat hyperglycemia

PhaseBio Pharmaceuticals has started a Phase IIa clinical trial of PE0139, a potential treatment for hyperglycemia associated with diabetes.

Duke U. obtains rights to PhaseBio's drug-delivery technology

The exclusive rights to PhaseBio Pharmaceuticals' elastin-like polypetide technology platform, a drug-delivery technology, ha -More- 

PhaseBio, Duke University deal

PhaseBio Announces Leadership Team Appointments

John S. Lee, M.D., Ph.D., named Chief Medical OfficerJohn P. Sharp, CPA, named Chief Financial Officer MALVERN, Pa., April 07, 2016 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-s...

PhaseBio to Present at Needham & Company’s 15th Annual Healthcare Conference

MALVERN, Pa., April 04, 2016 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and leader in the field of biopolymer-based drugs, focused on developin...

PhaseBio to Present at 23rd Annual Future Leaders in the Biotech Industry Conference

MALVERN, Pa., March 04, 2016 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and leader in the field of biopolymer-based drugs, focused on developin...

PhaseBio Receives FDA Orphan Drug Designation for Vasomera (PB1046) for the Treatment of Cardiomyopathy Associated With Dystrophinopathies

MALVERN, Pa., Dec. 1, 2015 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and leader in the field of biopolymer-based drugs, focused on developing trea...

Drugs and Medications [0 Results]

None

PubMed Articles [127 Associated PubMed Articles listed on BioPortfolio]

Removal of pharmaceuticals from secondary effluents by an electro-peroxone process.

This study compared the removal of pharmaceuticals from secondary effluents of wastewater treatment plants (WWTPs) by conventional ozonation and the electro-peroxone (E-peroxone) process, which involv...

Increased acute toxicity to fish caused by pharmaceuticals in hospital effluents in a pharmaceutical mixture and after solar irradiation.

Hospital effluents are an important source of residual drugs and other classes of pharmaceuticals in aquatic environments. The raw wastewater from the studied hospital exhibited acute toxicity to vert...

Ranking Prescribed Pharmaceuticals in Terms of Environmental Risk: Inclusion of Hospital Data and the Importance of Regular Review.

A newly available dataset on pharmaceuticals used in Scottish hospitals enabled an Environmental Risk Assessment that includes hospital consumption of pharmaceuticals, as previous UK rankings have bee...

Uptake, depuration, and bioconcentration of two pharmaceuticals, roxithromycin and propranolol, in Daphnia magna.

The objective of the present study was to investigate the uptake, depuration, and bioconcentration of two pharmaceuticals, roxithromycin (ROX) and propranolol (PRP), in Daphnia magna via aqueous expos...

Acute toxicities of pharmaceuticals toward green algae. mode of action, biopharmaceutical drug disposition classification system and quantile regression models.

The acute toxicities of 36 pharmaceuticals towards green algae were estimated from a set of quantile regression models representing the first global quantitative structure-activity relationships. The ...

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

PhaseBio Pharmaceuticals, Inc.

PhaseBio Pharmaceuticals, Inc. (PhaseBio), located in Research Triangle Park, NC, is a development stage, privately held protein engineering company focused on developing the next...

More Information about "PhaseBio Pharmaceuticals, Inc." on BioPortfolio

We have published hundreds of PhaseBio Pharmaceuticals, Inc. news stories on BioPortfolio along with dozens of PhaseBio Pharmaceuticals, Inc. Clinical Trials and PubMed Articles about PhaseBio Pharmaceuticals, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of PhaseBio Pharmaceuticals, Inc. Companies in our database. You can also find out about relevant PhaseBio Pharmaceuticals, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record